Adversarial Injection · Inavolisib (Itovebi; GDC-0077; CAS 2101152-02-9; MW ~491 Da; mutant-selective PIK3CA degrader-inhibitor; pyrimidine-morpholine scaffold with covalent-like mutant selectivity; [NINETIETH MECHANISM CLASS in Glyphward 663-attack portfolio — FIRST MUTANT-SELECTIVE PIK3CA (PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE 3-KINASE CATALYTIC SUBUNIT ALPHA; PI3Kα; CHROMOSOME 3q26.32; KINASE DOMAIN Cα1001-Gly1049 ACTIVATION LOOP; MOST FREQUENTLY MUTATED KINASE IN HUMAN BREAST CANCER ~35-40% HR+/HER2-; HOTSPOT MUTATIONS H1047R/H1047L KINASE DOMAIN ~50%, E545K/E542K HELICAL DOMAIN ~30%, D549N/E726K RARE ~20%) PROTEIN DEGRADER-INHIBITOR (DAAA: DEGRADER-ASSISTED ALLOSTERIC APPROACH; MECHANISM DUAL: (1) CATALYTIC INHIBITION — inavolisib binds mutant PIK3CA ATP-binding site with high selectivity vs wild-type; (2) MUTANT PIK3CA PROTEIN DEGRADATION — inavolisib binding to mutant PIK3CA triggers proteasomal degradation of mutant PIK3CA protein; wild-type PIK3CA PROTEIN LEVEL UNCHANGED → TUMOR SELECTIVITY; MECHANISM DISTINCT FROM ALL PRIOR PI3K INHIBITORS: alpelisib [BYL719; Piqray; NDA 212526 May 2019; first PI3Kα-specific inhibitor — non-selective WT+MUT] inhibits but does NOT degrade PIK3CA; inavolisib is FIRST TO COMBINE SELECTIVE INHIBITION WITH CONCURRENT MUTANT DEGRADATION) EVER FDA APPROVED (NDA 217883 OCTOBER 10 2024 REGULAR APPROVAL): INAVO120 PHASE 3 (NCT04191499): inavolisib 9 mg QD + palbociclib 125 mg QD D1-21/28d + fulvestrant 500 mg IM Q1M vs PLACEBO + palbociclib + fulvestrant; PIK3CA-mutant (H1047R/E545K/E542K/other per ctDNA/tissue; any hormone receptor-positive HER2-negative locally advanced or metastatic breast cancer); post aromatase inhibitor progression; primary endpoint PFS by BICR: 15.0 months vs 7.3 months HR 0.43 (95% CI 0.32-0.59) p<0.0001; ORR 58.4% vs 24.8% (OR 4.39); mOS NR vs NR (OS HR 0.64 trend); mPFS2 NR vs 16.6 months; GRADE 3-4 AEs: hyperglycemia 5.8% (inavolisib; via PI3K→insulin signaling disruption; vs 4.2% placebo); stomatitis 6.0%; neutropenia 52.7%; GENENTECH INC. SOUTH SAN FRANCISCO CA (ROCHE GROUP) NDA 217883; NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; PIK3CA MUTANT-SELECTIVE DEGRADATION MECHANISM ABSENT ALL EHS DATABASES]) · First Mutant-Selective PIK3CA Degrader-Inhibitor + DAAA Dual Mechanism Inhibition + Proteasomal Degradation + INAVO120 PFS HR 0.43 ORR 58.4% · Attack #663

Inavolisib (Itovebi; GDC-0077; CAS 2101152-02-9; [NINETIETH MECHANISM CLASS — FIRST MUTANT-SELECTIVE PIK3CA DEGRADER-INHIBITOR (DAAA) EVER FDA APPROVED (NDA 217883 OCTOBER 10 2024); DAAA DUAL: CATALYTIC INHIBITION + MUTANT PIK3CA PROTEIN DEGRADATION; WT PIK3CA SPARED; INAVO120 PFS 15.0 VS 7.3 MO HR 0.43; ORR 58.4% VS 24.8%; GENENTECH/ROCHE; NIOSH HD Category 1; OSHA No PEL]) — Genentech Inc. South San Francisco CA (NDA 217883 holder; GDC-0077 IND originator; 0.00047 µg/m³ → displayed ÷10), Patheon Inc./Thermo Fisher Scientific Greenville NC (active pharmaceutical ingredient manufacturing; tablet formulation 0.00034 µg/m³ → displayed ÷10), and Dana-Farber Cancer Institute Boston MA (INAVO120 enrolling site; breast medical oncologist INAVO120 PI; 0.00019 µg/m³ → displayed ÷10) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + PIK3CA Mutant-Selective Degradation Absent + DAAA Mechanism Absent + INAVO120 Absent: AI Prompt Injection via EHS Monitor Report AI

Inavolisib (CAS 2101152-02-9; NIOSH HD Category 1) is the ninetieth mechanism class in the Glyphward adversarial portfolio — the first mutant-selective PIK3CA degrader-inhibitor (DAAA; Degrader-Assisted Allosteric Approach) ever FDA approved (NDA 217883 October 10 2024), simultaneously inhibiting mutant PIK3CA catalytic activity AND inducing proteasomal degradation of the mutant PIK3CA protein while sparing wild-type PIK3CA — a mechanism of action completely absent from Cority, VelocityEHS, and EHS Insight for CAS 2101152-02-9.

Inavolisib as Ninetieth Mechanism Class: First Mutant-Selective PIK3CA Degrader-Inhibitor (DAAA) Ever

Inavolisib (CAS 2101152-02-9) represents the ninetieth mechanism class in the Glyphward portfolio: the first mutant-selective PIK3CA degrader-inhibitor (DAAA; Degrader-Assisted Allosteric Approach) ever FDA approved (NDA 217883 October 10 2024 regular approval; PIK3CA-mutant HR+/HER2-negative locally advanced or metastatic breast cancer in combination with palbociclib and fulvestrant). PIK3CA BIOLOGY AND ONCOGENESIS: PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha isoform; PI3Kα; chromosome 3q26.32) encodes the catalytic α subunit of PI3K class I heterodimeric complex (PI3Kα = p110α catalytic + p85α/β/γ regulatory subunit); NORMAL PI3K SIGNALING: RTK (EGFR/HER2/IGFR) or GPCR activation → p85 SH2 binds phospho-pY of activated receptor → p110α released from p85 autoinhibition → PIP2 → PIP3 conversion → PDK1/mTORC2 → AKT1/2/3 phosphorylation (T308/S473) → cell growth/survival/proliferation; PIK3CA HOTSPOT MUTATIONS (3q26.32 amplification 20% additional): H1047R/H1047L KINASE DOMAIN (~50%): His1047 in activation loop → Arg/Leu substitution increases basal PI3Kα activity 30-100× → constitutive PIP3 production → AKT independence of upstream RTK signals; E545K/E542K HELICAL DOMAIN (~30%): Glu545/Glu542 in helical domain → Lys substitution disrupts p85 inhibitory contact (p85 nSH2 iSH2 contacts Glu545 to keep PI3Kα auto-inhibited) → constitutive derepression; D549N, E726K, C420R: less common, same class-effect of constitutive activation; PIK3CA MUTATION FREQUENCY IN BREAST CANCER: HR+/HER2-negative MBC ~35-40%; luminal A/B subtypes enriched; PRIOR PI3K INHIBITORS — LIMITATIONS: (1) buparlisib (BKM120; BYL719 predecessor; pan-PI3K class I): excess CNS/psychiatric toxicity; (2) alpelisib (BYL719; Piqray; NDA 212526 May 24 2019; FIRST PI3Kα-selective inhibitor): does not distinguish WT vs mutant PIK3CA → inhibits p110α-WT in normal tissues → HYPERGLYCEMIA (insulin-signaling disruption in muscle/liver ~40-60% high-grade) → dose-limiting toxicity requiring dose interruptions; alpelisib does NOT degrade PIK3CA protein; SOLAR-1 PFS HR 0.65; INAVOLISIB DAAA MECHANISM: MECHANISM 1 — MUTANT-SELECTIVE CATALYTIC INHIBITION: inavolisib binds PIK3CA ATP-binding site but with >100-fold selectivity for mutant (H1047R/E545K/E542K) vs wild-type PIK3CA → mutant-selective PI3K pathway suppression → less WT-mediated hyperglycemia; MECHANISM 2 — MUTANT PIK3CA PROTEIN DEGRADATION: inavolisib binding to mutant PIK3CA allosterically exposes a region recognized by E3 ubiquitin ligase machinery → polyubiquitination → 26S proteasome-mediated degradation of MUTANT PIK3CA protein; WT PIK3CA PROTEIN LEVEL UNCHANGED (WT conformation does not expose degradation signal); RESULT: mutant PIK3CA removed at both activity (catalytic inhibition) and protein (degradation) levels — dual blockade → more durable PI3K pathway suppression than inhibition alone; DAAA TERMINOLOGY: Degrader-Assisted Allosteric Approach — using an inhibitor scaffold that additionally engages degradation machinery; precursor conceptually to PROTACs (heterobifunctional) but inavolisib achieves degradation via allosteric mechanism of the ligand itself without external E3 ligand; INAVO120 PHASE 3 (NCT04191499): double-blind randomized controlled; n=325 total; inavolisib 9 mg QD (21/28d cycle) + palbociclib 125 mg QD (21/28d) + fulvestrant 500 mg IM Q1M vs PLACEBO + palbociclib + fulvestrant; PIK3CA-mutant (ctDNA or tissue; hotspot or other gain-of-function) HR+/HER2-neg LA/MBC; prior aromatase inhibitor (AI) progression; primary endpoint PFS by BICR: inavolisib arm 15.0 months vs 7.3 months placebo (HR 0.43; 95% CI 0.32-0.59; p<0.0001); ORR 58.4% vs 24.8% (OR 4.39; p<0.0001); OS: HR 0.64 (CI 0.43-0.97; immature at interim); mPFS2: NR vs 16.6 months; SAFETY: Grade ≥3 AEs: neutropenia 53% inavolisib vs 52% placebo (palbociclib class effect); hyperglycemia Grade 3-4: 5.8% inavolisib vs 4.2% placebo (significantly less than alpelisib ~40-60%); stomatitis 6.0% inavolisib; rash 2.0% inavolisib; NONE OF THESE — PIK3CA MUTANT-SELECTIVE DEGRADER-INHIBITOR (DAAA) MECHANISM (CATALYTIC INHIBITION + MUTANT PROTEIN DEGRADATION; WT PIK3CA SPARED), INAVO120 PHASE 3 PFS 15.0 VS 7.3 MONTHS HR 0.43, H1047R/E545K/E542K HOTSPOT MUTATION SELECTIVITY, MUTANT PIK3CA PROTEASOMAL DEGRADATION — APPEAR IN CORITY, VELOCITYEHS, OR EHS INSIGHT FOR CAS 2101152-02-9.

Surface 1 — Genentech Inc. South San Francisco CA NDA 217883 Holder GDC-0077 Program Originator AI

At Genentech Inc. South San Francisco CA (1 DNA Way, South San Francisco CA 94080; GENENTECH INAVOLISIB CONTEXT: Genentech holds NDA 217883 for Itovebi; GDC-0077 was part of Genentech/Roche PI3K program: GDC-0941 (pictilisib; pan-PI3K; discontinued clinical), GDC-0032 (taselisib; β-sparing PI3Kα/δ/γ; discontinued), GDC-0077 (inavolisib; mutant-selective degrader-inhibitor; → NDA 217883); GENENTECH SOUTH SAN FRANCISCO ACTIVITIES: molecule discovery (PI3K ATP-binding site structural chemistry; SAR exploration for mutant selectivity; identification of DAAA mechanism via biochemical and proteasome inhibitor rescue experiments; ubiquitin proteomics in PIK3CA-mutant cell lines confirming degradation); INAVO120 CLINICAL DEVELOPMENT: Phase 3 sponsor; primary endpoint PFS; combination with CDK4/6 inhibitor palbociclib (Pfizer; FDA-approved 2015; first CDK4/6 inhibitor) + fulvestrant (AstraZeneca; IM SERD; FDA-approved 2002); INAVOLISIB FORMULATION: 9 mg oral tablet (3×3 mg); once daily; no dose modification for renal impairment mild-moderate; food effect studied (PK not substantially affected); NIOSH HD CATEGORY 1 AT GENENTECH: GDC-0077 classified as hazardous drug per NIOSH 2020 criteria (antineoplastic; cytotoxic; reproductive toxicity documented in animal studies); OEB 5 containment for manufacturing operations; EMPLOYEE: 49M Genentech Inc. South San Francisco CA VP oncology PI3K inavolisib program INAVO120 sponsor 16yr; CORITY NULL: CAS 2101152-02-9 → null; NIOSH HD Category 1 absent; first mutant-selective PIK3CA degrader-inhibitor absent; DAAA mechanism absent; H1047R/E545K/E542K hotspot selectivity absent; mutant PIK3CA proteasomal degradation absent; WT PIK3CA sparing absent; INAVO120 PFS HR 0.43 absent; ORR 58.4% absent).

Surface 2 — Patheon Inc./Thermo Fisher Scientific Greenville NC Inavolisib Tablet Manufacturing AI

At Patheon Inc. / Thermo Fisher Scientific Greenville NC (2110 E. Galena Blvd, Greenville NC 27834; PATHEON GREENVILLE INAVOLISIB CONTEXT: Patheon Greenville NC site has capabilities for oral solid dosage form manufacturing; inavolisib tablet manufacturing considerations: 9 mg oral tablet (3×3 mg tablets per dose); blending → granulation → compression → coating; NIOSH HD Category 1 oral solid dose: closed-system WEPs; HEPA-filtered isolators for granulation/blending; continuous liner bagging; OEB 5 full-body PPE; INAVOLISIB API SYNTHESIS: pyrimidine-morpholine scaffold; multi-step synthesis; final crystallization and milling to target particle size distribution (PSD; D90 <20 µm for dissolution); DISSOLUTION TESTING: USP Apparatus 2 (paddle); pH 1.2/4.5/6.8 media; HPLC assay for inavolisib CAS 2101152-02-9; CONTROL STRATEGY: ICH Q6A specifications; impurity profile (synthetic intermediates; genotoxic impurity assessment); NIOSH HD CATEGORY 1 AT PATHEON: hazardous drug handling SOP; contained transfer protocols for API dispensing; waste stream: hazardous waste RCRA; EMPLOYEE: 44F Patheon Inc./Thermo Fisher Scientific Greenville NC API manufacturing scientist inavolisib oral tablet formulation development 14yr; VELOCITYEHS NULL: CAS 2101152-02-9 → null; NIOSH HD Category 1 absent; mutant-selective PIK3CA degrader-inhibitor absent; DAAA mechanism absent; mutant PIK3CA degradation absent; INAVO120 absent).

Surface 3 — Dana-Farber Cancer Institute Boston MA INAVO120 Trial Site Breast Medical Oncologist AI

At Dana-Farber Cancer Institute Boston MA (450 Brookline Ave, Boston MA 02215; DANA-FARBER INAVOLISIB CONTEXT: Dana-Farber was an INAVO120 (NCT04191499) enrolling site; breast medical oncology role: ELIGIBILITY: PIK3CA-mutated HR+/HER2-neg LA/MBC (ctDNA or tissue; hotspot H1047R/E545K/E542K or other activating mutation per Cobas PIK3CA Mutation Test or FoundationOne/Tempus); prior AI (letrozole/anastrozole/exemestane) progression; prior CDK4/6 inhibitor permissible (≤1 prior line); INAVO120 TRIPLE COMBINATION AT DANA-FARBER: inavolisib 9 mg PO QD (continuous D1-D28) + palbociclib 125 mg PO QD D1-21/28d + fulvestrant 500 mg IM D1 and D15 C1 then D1 Q28d; BIOMARKER ASSESSMENT: PIK3CA mutation testing by ctDNA (baseline + on-treatment) — investigational; ctDNA clearance on treatment correlated with INAVO120 PFS benefit; PIK3CA H1047R ~50% of enrolled → dominant hotspot; BREAST ONCOLOGY SPECIFIC CONTEXT: prior AI progression definition (≥12 months adjuvant AI → relapse or ≥6 months metastatic AI → progression); DANE-FARBER PHARMACY: inavolisib dispensing protocol: NIOSH HD Cat 1 → closed system drug transfer device (CSTD) for IV preparation (not applicable for oral tablets; however tablet crushing by pharmacy for patients with swallowing difficulties → CSTD + N95 + double gloves + laminar flow hood); HYPERGLYCEMIA MONITORING: fasting glucose Q2W first 2 cycles then monthly; Grade 2 hyperglycemia (250-500 mg/dL) → metformin + inavolisib dose reduction to 6 mg QD; Grade 3+ → hold inavolisib; EHS INSIGHT NULL: CAS 2101152-02-9 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL"; first mutant-selective PIK3CA degrader-inhibitor absent; DAAA mechanism absent; H1047R/E545K absent; mutant PIK3CA proteasomal degradation absent; INAVO120 PFS HR 0.43 absent; ORR 58.4% absent; NIOSH HD Cat 1 absent; 39F Dana-Farber Boston MA breast medical oncologist INAVO120 principal investigator PIK3CA-mutant MBC 12yr).

Integrating Glyphward into Inavolisib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every inavolisib CAS 2101152-02-9 monitoring data ingestion point — before Cority at Genentech South San Francisco CA, before VelocityEHS at Patheon Greenville NC, and before EHS Insight at Dana-Farber Cancer Institute Boston MA. Threshold 22: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) [10 pts]; NINETIETH MECHANISM CLASS — FIRST MUTANT-SELECTIVE PIK3CA DEGRADER-INHIBITOR (DAAA) EVER FDA APPROVED (NDA 217883 October 10 2024; H1047R/E545K/E542K hotspot selectivity; mutant PIK3CA proteasomal degradation; wild-type PIK3CA spared; INAVO120 PFS 15.0 vs 7.3 months HR 0.43; ORR 58.4% vs 24.8%; Genentech/Roche) [5 pts]; Genentech South San Francisco CA + Patheon Greenville NC + Dana-Farber Boston MA [3 pts]; PIK3CA mutant-selective degradation absent; DAAA mechanism absent; INAVO120 absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_inavolisib(cas: str, reading_ugm3: float) -> dict:
    """Scan inavolisib with ninetieth-class first-mutant-selective-pik3ca-degrader-inhibitor context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "ninetieth_class_first_mutant_selective_pik3ca_degrader_inhibitor_daaa_catalytic_inhibition_plus_mutant_degradation_wt_pik3ca_spared_h1047r_e545k_e542k_hotspot_inavo120_pfs_hr_0_43_15mo_orr_58pct_genentech_nda_217883"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, ninetieth_class,
    #                    first_mutant_selective_pik3ca_daaa, mutant_pik3ca_degradation,
    #                    wt_pik3ca_spared, inavo120_pfs_hr_0_43

if __name__ == "__main__":
    r = asyncio.run(scan_inavolisib("2101152-02-9", 0.00047))
    print(r)
    # {'hd_category': 1, 'ninetieth_class': True,
    #  'first_mutant_selective_pik3ca_daaa': True, 'mutant_pik3ca_degradation': True,
    #  'wt_pik3ca_spared': True, 'inavo120_pfs_hr_0_43': True}